BOEHRINGER INGELHEIM ENTERS GLOBAL LICENSING AGREEMENT TO DEVELOP AND COMMERCIALIZE INNOVATIVE ANTIBODIES FROM A*STAR FOR TARGETED CANCER THERAPIES
2.6.2022 16:10:00 EEST | Business Wire | Press release
Boehringer Ingelheim and the Agency for Science, Technology and Research (A*STAR) today announced a global licensing agreement under which Boehringer Ingelheim will obtain exclusive worldwide rights to research, develop and commercialize products based on a panel of innovative, tumor-specific antibodies from A*STAR. Boehringer Ingelheim aims to use these antibodies to direct therapeutic effector mechanisms such as antibody-drug conjugates (ADCs) and T-cell engagers exclusively to tumor cells, and to that end develop a range of highly targeted cancer treatments.
“Boehringer Ingelheim believes that these promising antibodies in-licensed from A*STAR will help us advance potent therapeutic candidates against key molecular cancer targets,” says Clive R. Wood, Senior Corporate Vice President and Global Head of Discovery Research at Boehringer Ingelheim and continues: “We look forward to developing these assets for a broad range of cancers with the goal to deliver breakthrough opportunities for patients.”
Boehringer Ingelheim is pioneering a range of versatile therapeutic platforms in order to develop innovative medicines that target the tumor directly (tumor cell-directed therapies) or that enable the immune system to target the tumor (immune cell-targeted therapies). One tumor cell-directed modality is antibody drug conjugates, which allows for delivery of toxins directly into tumor cells. Another is T-cell engagers facilitating direct contact between T-cells and tumor cells, leading to T-cell-mediated killing of the tumor. Both technologies are directed towards markers on the surface of cancer cells, also known as antigens, in order to attack tumor cells but spare healthy tissues.
The innovative antibodies from A*STAR can potentially enable the development of safer, more efficacious therapies as they selectively bind to antigens that are highly expressed on tumor cells but are absent on normal healthy tissues.
Under the terms of the agreement, Boehringer Ingelheim will be responsible for further research, preclinical and clinical development as well as commercialization of targeted cancer therapies using the antibodies from A*STAR. A*STAR may receive payments totalling >100 million EUR in upfront and success-based development and commercialization milestones.
The technology used to identify the unique A*STAR antibodies resulted from a multi-institutional collaboration in Singapore. A*STAR’s Genome Institute of Singapore (GIS) and Institute of Bioengineering & Bioimaging (IBB) generated antibodies which exclusively target antigens that were initially identified from gastric cancer cells. Experimental Drug Development Centre (EDDC), Singapore’s national platform for drug discovery and development hosted by A*STAR, then optimized the antibodies and confirmed their applicability to a range of other solid cancers. EDDC also demonstrated the utility of these antibodies in directing different therapeutic modalities selectively to cancer cells.
Professor Damian O'Connell, Chief Executive Officer of EDDC, says, “As Singapore's national drug discovery and development platform, EDDC is proud to translate great science in Singapore into valuable assets that can enable the precise treatment of cancer. We believe that Boehringer Ingelheim, with its broad expertise and technologies, is the right partner to maximize the potential of these antibodies for the development of safer, more targeted therapies for cancer patients.”
Professor Tan Sze Wee, Assistant Chief Executive (Enterprise) of A*STAR, says, “These antibodies were developed in Singapore through close collaboration across multiple institutions. There was also strong support by the Singapore Gastric Cancer Consortium. The agreement is testament to the best-in-class research taking place in Singapore. Cancer is a devastating disease, and we hope the fruits of our research can improve patient outcomes.”
Please click on the link for “Note to Editors’ and ‘References’:
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220602005475/en/
Contact information
For media queries and clarifications:
Dr. Reinhard Malin
Innovation Unit Communications
Corporate Affairs
Boehringer Ingelheim
Tel: +49 6132 77-90815
Email: reinhard.malin@boehringeringelheim.com
Owen Sia
Assistant Head, Corporate Communications
Agency for Science, Technology and Research
Tel: +65 6517 7866
Email: owen_sia@hq.a-star.edu.sg
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ABB Robotics and PSYONIC Use Human-Generated Data to Advance Robotic Dexterity16.6.2026 07:01:00 EEST | Press release
ABB Robotics is collaborating with California bionics company, PSYONIC, to advance robotic gripping and dexterity using a new approach that utilizes real-world manipulation data from human prosthetic use. By combining the PSYONIC Ability Hand with an ABB GoFa™ cobot, the collaboration will explore how touch and motion data generated by human prosthetic use can be used to train robots to perform delicate, variable tasks that have traditionally been difficult to automate. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612749544/en/ “Human dexterity and the instinctive understanding of how to handle different objects is one of the most difficult things to replicate in industrial-grade robotics, but it’s a fundamental need for truly autonomous and versatile robots,” said Marc Segura, President, ABB Robotics. “As we develop the next generation physical AI, robots will learn and understand the world as we do. This collaboration
Signaloid Announces Availability of Amazon AWS Machine Image (AMI) for Accelerating Compute Workloads Ranging from Finance to Reinforcement Learning16.6.2026 07:00:00 EEST | Press release
British computing technology company Signaloid today announced the release of the Signaloid Compute Engine Amazon Machine Image (AMI) via AWS Marketplace. The release enables organizations to deploy Signaloid’s distribution-extended compute hardware (UxHw®) technology within their Amazon Virtual Private Clouds (VPCs). The AMI provides access to UxHw, which delivers orders-of-magnitude performance improvements on x86_64 and ARM (AArch64) AWS Elastic Compute Cloud (EC2) instances. Without requiring software rewrites, UxHw enables existing applications to compute directly on probability distributions, automating algorithms such as Monte Carlo methods in finance and physics, importance sampling in reinforcement learning, and particle filters in physical AI and robotics. The technology works through binary translation and optimization at the LLVM intermediate representation (LLVM IR) level, with optional hardware acceleration via FPGAs and Signaloid’s C0-ASIC that was recently taped-out in
Murata Collaborates with Synopsys to Provide Simulation Models Through Ansys Electromagnetic and Thermal Analysis Tools16.6.2026 05:00:00 EEST | Press release
Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) announces a new collaboration with Synopsys, Inc., enabling users of Synopsys' simulation tools to navigate directly to Murata's website to access and download the latest high-performance simulation models from Murata. The collaboration covers Synopsys' 3D electromagnetic field analysis tool Ansys HFSS™ and thermal analysis tool Ansys Icepak®, and marks a significant step toward streamlining the simulation workflow for electronic circuit designers. Murata is also the first company to offer passive component simulation models via Ansys Icepak*. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615241645/en/ [Murata Manufacturing Co., Ltd.] New collaboration with Synopsys As demand for high-speed, high-capacity communications continues to grow, electronic circuit design has become increasingly complex. Engineers must now account for a range of physical phenomena
Trimontium Launches with $1.5 billion in AUM, Redefining Flexible Capital Solutions16.6.2026 02:01:00 EEST | Press release
Trimontium (the “Firm”), an institutionally backed alternative asset manager specialising in flexible capital solutions, today announced its launch with $1.5 billion in assets under management. The Firm’s investment approach is rooted in credit and special-situations expertise, with the flexibility to originate and execute tailored financing solutions across the full capital structure for a wide range of corporate needs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615892895/en/ Trimontium Founder and CIO, Vlado Spasov Founded by former Blackstone executive Vlado Spasov, Trimontium is one of the largest first-time alternative asset managers based in Europe focused on flexible capital solutions to launch, according to available market data. The Firm is backed by leading institutional partners in the United States, Canada, Asia, and Australia, who collectively manage over $15 trillion in assets. Trimontium has sourced all
Newmont Announces Key Executive Appointments for the Next Phase of Delivery16.6.2026 00:20:00 EEST | Press release
Newmont Corporation (NYSE: NEM, ASX: NEM, PNGX: NEM) (“Newmont”) today announced leadership appointments that further shape its go-forward Executive Leadership Team under President and Chief Executive Officer Natascha Viljoen and reflect the depth of leadership talent within the company. Effective July 1, 2026, Brian Tabolt has been appointed Chief Financial Officer, Mark Rodgers has been appointed Chief Operating Officer, and David Thornton has been appointed Chief Technical Officer. In addition, David Fry has been promoted to Executive Vice President, Project Development, reflecting the importance of disciplined project development and execution as Newmont advances its highest-return growth opportunities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615487768/en/ Mark Rodgers - COO “These appointments bring together respected leaders with deep industry experience and a strong understanding of our operational, financia
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom